Hopkins researchers find that a vaccine used to treat cervical precancers can trigger an immune cell response
- Posted: January 31, 2014
Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.